ENXTPA:SANPharmaceuticals
Is Sanofi (ENXTPA:SAN) A Bargain As FDA Approval For Sarclisa Escena Expands Its Reach?
Sanofi (ENXTPA:SAN) is back in focus after US regulators cleared Sarclisa Escena, a subcutaneous version of its multiple myeloma therapy that can be delivered via on-body injector or manual injection, supported by non inferiority and safety data.
See our latest analysis for Sanofi.
Sanofi’s US approval for Sarclisa Escena comes as momentum in the stock has been mixed. The share price is at €77.1, with a 7 day share price return of 3.48%, but a year to date share price return that is down...